ChartRow logo
KNSA
$83.17+4.64%
as of close, Oct 20, 2026
☾ AH $83.17 +4.64%
PeersRDYNBIXELANSPYQQQNVDA
Share this page

Kiniksa Pharmaceuticals International plc trailing returns

How Kiniksa Pharmaceuticals International plc (KNSA) has performed over the last day, week, month and year, over 5 years, and since inception, through October 20, 2026 — price return and dividends side by side, with the worst drop inside each window.

Trailing returns by period#

To 2026-10-20. Price return + dividends = total return. Per year (CAGR) for windows of a year or more, with the cumulative total return beneath. Worst drop: the deepest fall in the price from a high inside the window, and when it bottomed.

PeriodPriceDivsTotalWorst drop
1 day+4.6%+0.0%+4.6%—
5 days+5.9%+0.0%+5.9%-1.7%Oct 16
1 month+7.7%+0.0%+7.7%-4.5%Sep 30
YTD+101.6%+0.0%+101.6%-21.1%Jun 2
1 year+113.3%+0.0%+113.3%-21.1%Jun 2026
5 years+50.2%+0.0%+50.2%+665.1%-49.8%Jun 2022
Since inception (2018)+18.9%+0.0%+18.9%+328.5%-83.1%Oct 2019

Growth of KNSA#

Actual level with dividends reinvested (solid); dashed lines are each window's constant-rate path from start to today.

  • 5 years+50.2%/year · +665.1%

Methodology#

Trailing returns measure from the closest close about N years before the latest close (2026-10-20). Cumulative return is the total change over the window; annualized return is the compound annual growth rate (CAGR), shown for windows of a year or more. Price return is the change in KNSA's closing price; total return reinvests dividends (from its split- and dividend-adjusted closes); the dividends column is the difference between the two. The worst drop is the largest fall in the closing price from a high to a later low inside the window, the way a drawdown is usually quoted. See the year-by-year returns for the calendar breakdown. Past performance does not predict future returns; not investment advice.

FAQ#

What is Kiniksa Pharmaceuticals International plc's return since inception?
Since 2018, Kiniksa Pharmaceuticals International plc (KNSA) has compounded at about +18.9% a year — +328.5% in total.

More on Kiniksa Pharmaceuticals International plc